Home' Australian Pharmacist : Australian Pharmacist April 2015 Contents Australian Pharmacist April 2015 I ©Pharmaceutical Society of Australia Ltd.
CONTINUING PROFESSIONAL DEVELOPMENT
KNOWLEDGE IN PRACTICE
The challenge of applying what
you learn to pharmacy practice!
Knowledge in practice is designed to
be difficult and aims to make you apply
information from articles in this month’s
Australian Pharmacist and other suggested
reading to the questions below, just as you
would for a client/patient. This section is not
meant to be easy. There are no simple clear-
cut answers to the questions. The standard
references listed below may be of use when
answering the questions.
1. Sansom LN, ed. Australian pharmaceutical
formulary and handbook, 23rd edn. Canberra:
Pharmaceutical Society of Australia; 2015.
2. Rossi S, ed. Australian medicines handbook.
Adelaide: Australian Medicines Handbook; 2015.
3. National Prescribing Service. At: www.nps.org.au
4. Merck Manual of Diagnosis and Therapy.At: www.
5. Product information – available from various
sources, e.g. MIMS, APP Guide or online on
6. Royal College of Pathologists of Australasia. RCPA
Manual. At: www.rcpamanual.edu.au
7. Therapeutic Guidelines Series. eTG complete.
Melbourne: Therapeutic Guidelines Limited.
Knowledge in practice
TO ANSWER KNOWLEDGE IN
Answers for Knowledge in practice can only be
submitted online through the PSA members-only
area of the PSA website at: www.psa.org.au
PSA members will receive instant feedback on
the correct answers with an explanation of why
the answer is correct. If you do not have member
access details for the PSA website, you can request
them via a link from the login page.
Question 1. Medication review
Additional reference: Clinical guidelines for stroke management. Melbourne: National Stroke Foundation;
2010. At: http://strokefoundation.com.au/site/media/clinical_guidelines_stroke_managment_2010_
Mr Church, a 76‐year‐old long‐term
smoker (55 pack‐year history), is referred
for a Home Medicines Review (HMR).
He has been hospitalised three times in
the past six months with exacerbations
of COPD (chronic obstructive pulmonary
disease) and pneumonia, with the most
recent admission being complicated
by Clostridium difficile colitis. He has a
medical history of:
• Barrett’s oesophagus
• prostate cancer
• transient ischaemic attack (2009,
His current medications are:
• amlodipine (Norvasc) 10 mg in the
• atorvastatin (Lipitor) 10 mg at night
• bicalutamide (Cosudex) 150 mg in the
• calcium carbonate (Caltrate) 1,500 mg
in the morning
• colecalciferol (Ostevit-D) 25 mcg in
• esomeprazole (Nexium) 20 mg at
night when required (approximately
once every two months)
• fluticasone/vilanterol (Breo)
200/25 mcg one inhalation in the
• salbutamol 100 mcg 1–2 inhalations
• sildenafil (Viagra) 50 mg when
• thyroxine (Eutroxsig) 100 mcg in the
• tiotropium (Spiriva) 18 mcg one
inhalation in the morning.
During the HMR interview, Mr Church
tells you that he generally feels ‘quite
well’, although he is concerned that
he is forgetting to take some of his
medications. He has also experienced
hot flushes and mood swings since
commencing bicalutamide, and his
specialist is considering changing it to
Which ONE of the following statements
regarding Mr Church’s management is
the MOST appropriate at this time?
a) There is strong evidence that he should
take esomeprazole regularly, based on his
medical history and current health status.
b) Changing bicalutamide to leuprorelin
is unlikely to adversely affect any of his
other medical conditions.
c) He should be instructed to take all
of his medications as a single dose
in the morning, to assist him with his
d) He should commence an antiplatelet
agent such as aspirin/dipyridamole
for the secondary prevention of
Through successful completion of this activity, the
learner will demonstrate their ability to:
• Use readily available information sources to
access and select relevant and up-to-date
clinical and practice-based information
• Promote and contribute to the optimal use of
• Address primary healthcare needs of patients.
Competency standards (2010) addressed: 4.2,
6.1, 7.1, 7.2 .
Accreditation number: CAP150404F
Links Archive Australian Pharmacist March 2015 Australian Pharmacist May 2015 Navigation Previous Page Next Page